Teachers Retirement System of The State of Kentucky Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Teachers Retirement System of The State of Kentucky lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.2% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,494 shares of the biopharmaceutical company’s stock after selling 852 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Regeneron Pharmaceuticals were worth $16,285,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. 3Chopt Investment Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $565,000. Kimelman & Baird LLC purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at about $57,000. B. Riley Wealth Advisors Inc. increased its stake in Regeneron Pharmaceuticals by 8.0% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 1,086 shares of the biopharmaceutical company’s stock valued at $1,142,000 after purchasing an additional 80 shares in the last quarter. Ironwood Investment Management LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter worth about $210,000. Finally, Seaport Global Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 64.2% during the second quarter. Seaport Global Advisors LLC now owns 839 shares of the biopharmaceutical company’s stock valued at $882,000 after buying an additional 328 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.4 %

Shares of REGN stock opened at $1,046.91 on Wednesday. The company has a market capitalization of $115.41 billion, a price-to-earnings ratio of 30.93, a PEG ratio of 3.56 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The company’s fifty day moving average price is $1,128.37 and its 200-day moving average price is $1,036.74. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $8.79 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on REGN. Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Argus upped their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Truist Financial reiterated a “buy” rating and issued a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 25th. Finally, Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,118.62.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The disclosure for this sale can be found here. Insiders sold a total of 8,033 shares of company stock valued at $9,399,345 in the last three months. 7.48% of the stock is currently owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.